ChemomAb Ltd.

6 clinical trials · Sponsor

Record	Firm	Date
Study to Evaluate the Safety, Tolerability, and Activity of CM-101 in Patients With Systemic Sclerosis (NCT06210945)	ChemomAb Ltd.	2026-09-01
CM-101 in NASH Patients - The SPLASH Study (NCT05824156)	ChemomAb Ltd.	2021-02-24
CM-101 in PSC Patients -The SPRING Study (NCT04595825)	ChemomAb Ltd.	2020-10-01
Subcutaneous Doses of CM-101 as a Treatment for Medical Conditions Involving Inflammatory and Fibrotic Mechanisms in Healthy Male Subjects (NCT06037577)	ChemomAb Ltd.	2019-03-05
The Study of Multiple Doses of CM-101 in Male and Female NAFLD (Nonalcoholic Fatty Liver Disease) and NAFLD/NASH (Nonalcoholic Steatohepatitis) Subjects (NCT06044467)	ChemomAb Ltd.	2018-12-11

Every clearance here is in the API, with alerts when new ones post.